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REVIEW

Latrepirdine: molecular mechanisms underlying potential
therapeutic roles in Alzheimer’s and other neurodegenerative
diseases
PR Bharadwaj1, KA Bates2, T Porter1, E Teimouri1, G Perry3, JW Steele4, S Gandy5, D Groth6, RN Martins1,7,8 and Giuseppe Verdile1,7,8,9
Latrepirdine (DimebonTM) was originally marketed as a non-selective antihistamine in Russia. It was repurposed as an effective
treatment for patients suffering from Alzheimer’s disease (AD) and Huntington’s disease (HD) following preliminary reports showing
its neuroprotective functions and ability to enhance cognition in AD and HD models. However, latrepirdine failed to show efﬁcacy
in phase III trials in AD and HD patients following encouraging phase II trials. The failure of latrepirdine in the clinical trials has
highlighted the importance of understanding the precise mechanism underlying its cognitive beneﬁts in neurodegenerative
diseases before clinical evaluation. Latrepirdine has shown to affect a number of cellular functions including multireceptor activity,
mitochondrial function, calcium inﬂux and intracellular catabolic pathways; however, it is unclear how these properties contribute
to its clinical beneﬁts. Here, we review the studies investigating latrepirdine in cellular and animal models to provide a complete
evaluation of its mechanisms of action in the central nervous system. In addition, we review recent studies that demonstrate
neuroprotective functions for latrepirdine-related class of molecules including the b-carbolines and aminopropyl carbazoles in AD,
Parkinson’s disease and amyotrophic lateral sclerosis models. Assessment of their neuroprotective effects and underlying biological
functions presents obvious value for developing structural analogues of latrepirdine for dementia treatment.
Translational Psychiatry (2013) 3, e332; doi:10.1038/tp.2013.97; published online 3 December 2013
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INTRODUCTION
With an ageing population, there is a need for both preventative
and disease-modifying treatments for Alzheimer’s disease (AD).
Current AD treatments target cognitive decline and provide
only minor beneﬁts across the array of clinical symptoms.1,2
Approved AD drugs such as acetylcholine esterase (ACE) inhibitors
(donepezil, rivastigmine and galanthamine) and N-methyl-D-aspartate (NMDA) receptor antagonists (Memantine) are generally
prescribed as monotherapy or in combination. However, approved
AD drugs are expensive and, most importantly, do not prevent
disease progression and are of limited beneﬁt to most patients.3,4
Latrepirdine was initially used in Russia in 1983 as a nonselective antihistamine for the treatment of skin allergy and
allergic rhinitis.5–7 Studies outlining the signiﬁcance of antihistamine drugs in treating neurodegenerative disorders and the
neuroprotective functions of latrepirdine in animal models
initiated interest for repurposing latrepirdine as a potential
therapy for AD and Huntington’s disease (HD). Despite the lack
of understanding of latrepirdine’s mechanism of action in the
central nervous system, it was evaluated in clinical trials for AD8
and HD9 (Table 1). A pilot clinical trial performed on 14 patients
with mild–moderate AD supported the results of the cellular and

animal studies. Signiﬁcant improvement in both cognitive
function and psychiatric symptoms was observed in all patients
undergoing latrepirdine treatment. Also, a distinct antidepressive
effect was observed in AD patients.5 In 2008, data from a phase II
randomized, double-blind, placebo-controlled study conducted in
Russia demonstrated for the ﬁrst time, improvement across a
range of clinical outcomes due to a therapeutic intervention in
mild–moderate AD.8 Phase III trials, CONNECTION and CONTACT
were then launched and results released in early March 2010
showed no improvement in any primary or secondary outcome
measures of cognition in the patients.10 Similar to the outcomes in
AD clinical trials, phase III trial of latrepirdine in HD patients failed
to show efﬁcacy in the 6-month HORIZON trial, which enrolled 403
people with HD in 11 countries.11 In contrast to the cognitive
beneﬁts observed in phase II trials, no signiﬁcant improvements
over placebo-treated patients were observed in HD patients
administered latrepirdine.9
It is evident that latrepirdine trials in HD and AD have
progressed to phase III trials based on an encouraging phase II
trial data. It is although uncertain whether the failure of
latrepirdine in phase III can be attributed to the poor efﬁcacy of
the drug or due to the lack of trial optimization. The beneﬁts of
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n ¼ 56

Mild-to-moderate HD
(430 years of age,
X36 CAG
polyglutamate repeat
expansion)
Paranoid
schizophrenia on
risperidone

Moderate-to-severe
AD on memantine
Mild-to-moderate HD

Moderate-to-severe
AD on donezepil

35–50 years

30 years and older

52–53 years/25.1–25.6

Terminated

Terminated

50 years and
older/12–24

74.4 years/17.7

68 years/18.7

64–68 years

Average age/MMSE
at baseline

4–8 weeks
4–6 mg risperidone
N ¼ 29 20 mg t.i.d.
N ¼ 27 Placebo

90 days
N ¼ 46 20 mg t.i.d.
N ¼ 45 placebo
6 months
20 mg t.i.d.
Placebo

PANSS, CGI-S

UHDRS
MMSE
ADAS-cog
MMSE
CIBIC-plus

N/A

N/A

ADCS-ADL
ADAS-cog

ADAS-cog CIBIC-plus

ADAS-cog
CIBIC-plus

Hazegawa scale
(MMSE equivalent)

8 weeks, 20 mg t.i.d.a
6 months,
N ¼ 89 on 20 mg t.i.d.
N ¼ 94 on placebo
6 months
N ¼ 1/3 5 mg t.i.d.
N ¼ 1/3 20 mg t.i.d.
N ¼ 1/3 placebo
12 months
N ¼ 1/3 5 mg t.i.d.
N ¼ 1/3 20 mg t.i.d.
N ¼ 1/3 placebo
6 months
20 mg t.i.d.
Placebo
N/A

Primary end points
(functional)

Treatment regimen

Improvement of negative
symptoms and certain
components of cognitive
dysfunction

No change in UHDRS,
significant improvement
in cognition (MMSE only)
No change in any primary
or secondary outcome
measures

N/A

N/A

No change in any primary
or secondary outcome
measures

Significant improvement
of cognitive and selfservice functions
Significant improvement
in cognition over placebo
and baseline levels
No change in any primary
or secondary outcome
measures

Outcome

86

11

9

85

10

83,84

83

8

5

Reference

Abbreviations: AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; ADCS-ADL, Alzheimer’s disease co-operative study-activities of daily living; CGI-S, Clinical Global
Impression-Severity Scale; CIBIC: Clinician’s Interview Based Impression of Change-Plus Caregiver Input; HD, Huntington’s disease; MMSE, mini mental state examination; N/A, not available; PANSS, Positive and
Negative Syndrome Scale; t.i.d., three times daily; UHDRS, Unified Huntington’s Disease Rating Scale. aNote, no placebo control arm was used in this study.

Russia
(phase II)

64 sites
n ¼ 403

17 sites
n ¼ 91

N/A

CONSTELLATION

DIMOND
US and UK
(phase II)
HORIZON
North America, Europe and
Australia

N/A

Mild–moderate AD on
donepezil

n ¼ 1050

CONTACT
Europe and South America

Mild–moderate AD

63 sites
n ¼ 598

CONNECTION
(phase III)
North and South America,
Europe
CONCERT
USA, UK, Europe, Australia
and New Zealand

Mild–moderate AD

Mild–moderate AD

11 sites
n ¼ 183

14

Patient type

Russia
(phase II)

Russia
(pilot/phase I)

Number of
participants

Latrepirdine clinical trials for Alzheimer’s, Huntington’s disease and schizophrenia

Trial name and country

Table 1.
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latrepirdine in the phase II AD study were not driven by worsening
in the placebo group, but reﬂected an absolute improvement on
latrepirdine as well as a decline on placebo. In the phase III trial,
however, the patients in the trial did not deteriorate signiﬁcantly
in either the drug-treated group or the placebo group, which
makes interpretation of the study more difﬁcult. There are also
some notable differences between the Russian phase II study and
the multinational phase III studies including the formulation of
latrepirdine, baseline mini mental state examination (MMSE) and
the age of the patients recruited (mean age 68.1 years in phase II
versus 74.4 years in phase III).8,10 Unfortunately, concerning the
disease-modifying activity of latrepirdine, no brain amyloid load
(Pittsburgh Compound-B-positron emission tomography (PIB-PET)
imaging) or biomarker data are available from the different clinical
trials as only ADAS-cog (Alzheimer’s Disease Assessment Scalecognitive subscale) was used as primary outcome.
One of the other major criticisms for the mixed outcomes from
the AD and HD clinical trials was directed toward the lack of
optimization of the trial design and the lack of clarity in the drug’s
mechanism of action responsible for its cognitive-enhancing
properties. Several possible neuroprotective functions for latrepirdine have been postulated; however, there is a need to
rigorously test and verify the mechanisms of action of latrepirdine
and establish the dose that is most likely to be effective.12,13 In
addition to its well-known antihistamine properties, studies have
demonstrated cognitive-enhancing properties in non-transgenic
healthy animal models and in neurodegenerative models.5,14–16
Studies have reported latrepirdine’s ability to inhibit a number of
neurotransmitter receptors, modulate Ca2 þ metabolism, protect
mitochondrial function5,17,18 and more recently its ability to
modulate intracellular catabolic pathways and reduce amyloid
aggregates and pathology in cellular and mice models.15,19–22
Unfortunately, target validation and the magnitude of the
impact of these putative actions on key disease processes and
clinical symptoms have not been robustly clariﬁed. Here, we
review the studies investigating the different mechanisms of
action of latrepirdine in cellular and animal models, to evaluate its
potential role in the treatment of AD and other neurodegenerative
diseases.
MECHANISMS OF ACTION
Antihistamine and cognitive properties
Latrepirdine blocks H1 histamine receptor activity and hence was
used as an antihistamine drug for the treatment of burns, allergic
rhinitis and skin allergy in Russia since 1983. However, its use as an
antihistamine declined with the discovery of more selective
drugs.6,23 Studies also have reported antiarrhythmic properties
and an effect on coronary blood ﬂow and myocardial contractibility,24,25 even though the possible underlying mechanisms have
not yet been determined. More recently, interest in latrepirdine
rebounded following a growing interest in the role of histamine
receptors (5-hydroxytryptamine 6 (5-HT6) and 5-HT7) in learning
and cognitive functions26,27 and studies reporting cognitiveenhancing and neuroprotective functions of latrepirdine.5,15 In
addition to blocking the histamine receptor activity, latrepirdine
has been shown to interact with calcium channels and a wide
range of other neurotransmitter receptors.
Multireceptor activity and modulation of calcium channels
Neurotoxicity and loss of neuronal processes caused by excitatory
amino acids, glutamate and aspartate is a characteristic feature of
several neurodegenerative diseases. The toxic action of glutamate
and aspartate is largely receptor-mediated leading to an increase
in the intracellular Ca2 þ concentration that triggers a cascade of
pathological reactions causing the death of nerve cells.28,29
Studies indicate that intracellular calcium (Ca2 þ ) ﬂux is critical in
& 2013 Macmillan Publishers Limited

synaptic plasticity, a cellular mechanism for learning and memory.
Therefore, modulators of Ca2 þ channels and receptor functions
regulating calcium inﬂux are currently a focus of interest for their
potential use as neuroprotective agents.30–32 In the Bachurin et al.5
study, latrepirdine suppressed Ca2 þ -induced contractions of
smooth muscles in a reversible and concentration-dependent
manner. Similar effects of latrepirdine were observed in neuronal
cultures from wild-type mice and HD transgenic mice, which
harbour the entire human HD gene containing 128 CAG repeats.
Also, latrepirdine was found to act as an inhibitor of NMDA
receptors and voltage-gated calcium channels. Application of
latrepirdine stabilized glutamate-induced Ca2 þ signals and
conferred protection from glutamate-induced apoptosis.16
In one of the initial studies, the effects of latrepirdine on AMPA
(a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and
NMDA subtypes, glutamate receptors in rat cerebral neurons,
were evaluated in a comparative study against memantine, a
potent NMDA receptor antagonist.33 Both latrepirdine and
memantine in low concentrations potentiated activity of AMPA
receptors in rat cerebellar Purkinje cells. In rat cortical neurons,
both latrepirdine and memantine efﬁciently blocked NMDA
receptor activity with different potencies. The differences in the
effects of memantine and latrepirdine may be determined by their
interaction with different channel and/or receptor subunits of
NMDA receptors. For example, the polyamine site of the NMDA
receptor NR2B subunit34 has been suggested as a possible binding
site for latrepirdine.
Interactions between latrepirdine and a number of molecular
targets including ACEs, a-adrenergic, serotonergic and dopaminergic receptors have been reported.5,33,35,36 These receptors are
widely distributed in the brain and are associated with different
neuropsychiatric symptoms37,38 including hallucinations and
depression in AD patients.39,40 Evaluation of latrepirdine against
a set of biochemical targets indicated that it inhibits a-adrenergic
receptors (a1A, a1B, a1D and a2A), histamine H1 and H2 receptors
and serotonin 5-HT2c, 5-HT5A and 5-HT6 receptors.16,41
In a recent study, molecular pharmacology proﬁling of
latrepirdine was performed on a panel of 70 targets including
enzymes, ion channels, neurotransmitter transporters and G-protein-coupled receptors to characterize the spectrum of its
activity.17 In addition to histaminergic receptors, latrepirdine
exhibited high afﬁnity to a range of other receptors; speciﬁcally,
serotonergic, a-adrenergic and dopaminergic receptors.
Latrepirdine was found to interact with relatively low afﬁnity
with some ion channels (benzothiazepine site of L-type Ca2 þ
channel, site 2 of sodium channel and hERG (human ether-a-gogo-related gene) potassium channel) and the norepinephrine
transporter. Owing to its broad spectrum activity on many therapeutically important neuronal receptors, it is unclear how
latrepirdine’s molecular pharmacology relates to its multifunctional effects on different aspects of central nervous system
activity.
Neuroprotective and cognitive-enhancing functions in animal
models
Latrepirdine has been shown to possess neuroprotective functions
and improve memory in animals with drug-induced cognitive
impairment. In the initial work by Shadurskaia et al.,42 latrepirdine
was shown to possess neuroactive functions including its ability to
inhibit monoamine oxidase deaminating dopamine and serotonin,
thereby increasing dopamine and noradrenaline in the rat brain.42
It was shown that latrepirdine is a potent competitive and
reversible inhibitor of both ACE and butyrylcholine esterase, which
are key enzymes associated with the degradation of acetylcholine
in the brain.43
Systemic administration of latrepirdine restored memory as
determined by two-way active avoidance performance in rats
Translational Psychiatry (2013), 1 – 9
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injected with AF64A (L-ethyl-1-(2-hydroxyethyl) aziridinium, a
neurotoxic analogue of acetylcholine that causes neurodegenerative changes characteristic of AD.44 The data suggested that
latrepirdine activated compensatory mechanisms against chronic
partial deprivation of cerebral cholinergic functions, which may be
responsible for the prevention of neurodegeneration in AF64Ainjected rats.15 In a subsequent study, latrepirdine showed a dosedependent prevention of convulsions and death caused by
NMDA-induced toxicity in mice and protected cerebellar granule
cells against b-amyloid 25–35 (Ab25–35), a neurotoxic fragment of
Ab protein.5 Latrepirdine also increased survival rate of serumstarved differentiated neuroblastoma cells.18
In a more recent study, latrepirdine administered before
methamphetamine signiﬁcantly reduced the amount of striatal
dopamine depletion in mice, suggesting that latrepirdine may be
exerting a neurotoxin-speciﬁc protective effect.45 Besides its
neuroprotective effects, administration of latrepirdine has also
shown to promote hippocampal-dependent learning in both
appetitive and inhibitory tasks in mice.46 However, in a more
recent report, latrepirdine failed to exert any effect on the agerelated impairment in spatial learning and performance assessed
using the Morris water maze. Latrepirdine also showed no effect
on the age-related increase in hippocampal expression of markers
of microglial and astroglial activation in rats.47 This study suggests
that the cognitive-enhancing and neuroprotective properties of
latrepirdine may be limited to the degeneration of speciﬁc
neuronal functions and associated cognitive abilities. In addition
to rodent models, latrepirdine has been shown to enhance
memory and learning in a primate model. Acute latrepirdine
administration was associated with modest improvements in the
performance of a delayed matching to sample task in young adult
and aged monkeys and showed a trend towards attenuation of
scopolamine-induced impairments in young adult monkeys.48
Recent studies have provided further insight into the potential
mechanisms of action that may underlie latrepirdine’s cognitiveenhancing properties. Acute oral administration of latrepirdineenhanced cognition in rats but did not alter the activity of
acetylcholine (ACE) nor block NMDA-induced calcium inﬂux,
suggesting that the cognition-enhancing effects of latrepirdine
are unlikely to be mediated by ACE inhibition or NMDA receptor
antagonism.49 Latrepirdine was compared against SB-399885
(selective 5-HT6 antagonist50) to evaluate the role of antihistamine activity to cognitive functions. The afﬁnity and
potency of latrepirdine for 5-HT6 receptor were signiﬁcantly
lower than that observed with the selective 5-HT6 antagonist
SB-399885. Consistent with its activity at the 5-HT6 receptor,
latrepirdine was signiﬁcantly less potent than SB-399885 in the
improvement of memory functions.41 It is important to note that
latrepirdine interacts with several other receptor molecules and
that these interactions have not been fully characterized. As many
of these targets signiﬁcantly impact cognitive function, the
relative role of 5-HT6 receptor antagonism in the clinical efﬁcacy
of latrepirdine remains speculative. Latrepirdine was also found to
be proneurogenic in an in vivo screen in adult mice.19 Although it
showed lower activity compared with the lead compound P7C3,
an aminopropyl carbazole, latrepirdine administration showed
signiﬁcant increase in hippocampal neurogenesis in the mouse
model.19 This study provided further evidence for latrepirdine’s
cognitive-enhancing properties; however, no speciﬁc target or
mechanism responsible for its actions was indicated.
Latrepirdine treatment in neurodegenerative disease models
Recent studies provide evidence for a neuroprotective effect of
latrepirdine in transgenic mouse models of neurodegenerative
disease. Latrepirdine has been shown to modulate amyloid
pathology, reduce memory deﬁcits in transgenic AD mice and
protect against Ab toxicity in cultured cells.5,18,51 TgCRND8 mice52
Translational Psychiatry (2013), 1 – 9

treated with latrepirdine exhibited a trend towards cognitive
and behavioural improvement without affecting the levels of total
Ab in the brain.53 In our recent work, TgCRND8 mice were
administered with latrepirdine and subjected to behaviour
analysis in the cued and contextual fear conditioning paradigm,
as well as immunohistological and biochemical analysis of
AD-related neuropathology. Latrepirdine treatment was
associated with improved learning behaviour and with a
reduction in the accumulation of Ab42 and a-synuclein.21,22
The effects of latrepirdine have also been studied in other
neurodegenerative disease models including Parkinson’s disease
(PD) and amyotrophic lateral sclerosis (ALS). In an overexpressing
synuclein mice model (Thy1mgSN), chronic administration of
latrepirdine was shown to signiﬁcantly reduce the development of
motor dysfunction and coordination.14 However, a more recent
study showed no improvement in motor skills or changes in the
levels of striatal dopamine or a-synuclein in the brains of
transgenic mouse model characterizing early-stage PD.54 Also,
latrepirdine did not block 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated cell death of dopaminergic neurons in
Caenorhabditis elegans or in the substantia nigra of adult mice.55
Chronic latrepirdine administration was studied in a mouse model
of g-synucleinopathy characteristic of the pathological features of
ALS. Signiﬁcant improvement of motor performance, reduced
amyloid inclusions, decreased amount of insoluble g-synuclein
species and a notable amelioration of astrogliosis were observed
in the latrepirdine-treated animal groups.56 However, in a more
recent study, latrepirdine did not protect the spinal cord motor
neurons from cell death or preserved the motor function in a
mouse model of ALS.57 Latrepirdine treatment also conferred no
protection against the toxicity associated with expression of
ALS-associated genes TDP43 and FUS, and the HD-associated
protein huntingtin with a 103 copy-polyglutamine expansion (htt103Q) in yeast. These results indicate that latrepirdine’s neuroprotective functions are limited to speciﬁc neurodegenerative
mechanisms. Further analysis of latrepirdine’s proposed neuroprotective effects and pathological markers including the accumulation of the misfolding protein, levels of neurotransmitters and
receptor activities in these disease models can provide a greater
insight into its mechanisms of action in vivo.
There is increasing evidence describing latrepirdine’s neuroprotective effects, but the mechanisms underlying these cognitive
beneﬁts have remained elusive. During the past few decades, the
concept of multitarget drug activity has been proposed.58,59. On
the basis of this concept, the mechanisms responsible for the
beneﬁcial actions of latrepirdine may be attributed to multiple
downstream effects on a number of receptors leading to change
in neurotransmitter levels.
Mitochondrial activity
Mitochondrial dysfunction is a common feature of several
neurodegenerative diseases including AD. In the AD brain, there
is a characteristic decrease in the number of mitochondria in
neurons accompanied by decreased brain glucose metabolism,60
and reduced activities of both tricarboxylic acid cycle enzymes61
and cytochrome c oxidase.62,63 A number of studies have reported
the protective effects of latrepirdine on mitochondrial structure,
function and metabolism, some of which have also been indicated
as the underlying mechanism of its proneurogenic properties. In
the initial report, latrepirdine was shown to modulate the
mitochondrial permeability transition pore (PTP). PTP regulates
the transport of Ca2 þ and smaller compounds in and out of
the mitochondria. Latrepirdine suppressed the opening of PTP by
neurotoxins including MPP þ (1-methyl-4-phenylpyridinium),
Ab25–35, phosphate ions, calcium ions or by butylhydroxyperoxide in isolated rat liver mitochondria.35 In the same study,
latrepirdine was shown to suppress lipid peroxidation induced by
& 2013 Macmillan Publishers Limited
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either butylhydroperoxide or by Ab25–35. Although no direct
evidence for the relationship between suppression of lipid
peroxidation and inhibition of PTP opening was identiﬁed, these
properties may be a contributing factor in the protection of
mitochondrial function and in the overall neuroprotective effect
of the latrepirdine.35 In a more recent study, similar effects of
latrepirdine on calcium-induced permeability transition were
observed in the mitochondria isolated from rat brain.
Latrepirdine attenuated Ca2 þ -induced swelling but did not alter
cytochrome c release or Ca2 þ uptake capacity. The ﬁndings
showed that latrepirdine reduced mitochondrial swelling without
inducing any major changes in permeability transition.64
In primary mouse cortical neuronal cells and human neuroblastoma cells, latrepirdine improved mitochondrial function on
aspects such as mitochondrial membrane potential and ATP
synthesis, although the drug’s effect on PTP opening was not
determined.18 Also, no change in the mitochondrial DNA copy
number was observed with latrepirdine treatment, implying no
effect on mitochondrial biogenesis.18. In an in vivo screen for
search of novel proneurogenic compounds, latrepirdine was
shown to protect mitochondrial membrane integrity at high
concentrations.19 In a more recent study, the effects of latrepirdine
were tested on mitochondrial function and dynamics in a cellular
model, overexpressing neurotoxic Ab peptides. Here, latrepirdine
was shown to protect against the toxic effects of Ab on
mitochondrial morphology, respiratory chain complex activities
and enlarged mitochondrial mass.65 Further support for the
potential role of latrepirdine in the enhancement of mitochondrial
function and subsequent energy homeostasis comes from one
study that showed latrepirdine to be signiﬁcantly enhanced by
cerebral glucose utilization in aged mice, whereas no effect on
CGU was observed in the young mice.66
Regulate protein aggregation
Progressive accumulation of misfolded or aggregate proteins in
the brain is a characteristic feature of neurodegenerative diseases
including ALS (TAR DNA-binding protein 43, TDP-43), PD
(synuclein), HD (Huntington protein, mHTT) and AD (beta amyloid,
Ab). Agents that reduce aggregation and accumulation of
amyloidogenic proteins in the brain have shown to improve or
arrest the cognitive deﬁcits and behavioural symptoms in animal
models.67–69 Recent studies have suggested that the ability to
modulate accumulation or generation of protein aggregates in the
brain may contribute to the neuroprotective and cognitiveenhancing functions of latrepirdine.
The effects of latrepirdine on the formation of TDP-43
aggregates were investigated in human neuroblastoma cells.
Latrepirdine treatment reduced the number of TDP-43 aggregates
as measured by immunoblot analysis. In combination with
methylene blue, latrepirdine treatment further reduced the level
of aggregates in cells.70 Latrepirdine treatment signiﬁcantly
reduced the number of amyloid deposits in the spinal cord
associated with reduced development of motor dysfunction and
astrogliosis in the Thy1mgSN mouse model.14 In a more recent
study, the effects of latrepirdine on the formation of ﬁbrillar
detergent-insoluble structures formed by GS protein (the main
component of pathological intracellular incorporations in the
neurons of Thy1mgSN mice) were studied.71 This study revealed a
signiﬁcant reduction of aggregated synuclein forms in specimens
of spinal cord tissue from latrepirdine-treated mice. However, no
change in the levels of intermediate protein aggregation products,
oligomers and protoﬁbrils was observed with latrepirdine
treatment.
In a more recently published work, the effects of latrepirdine
upon Ab, tau and astrogliosis in the hippocampus of triple
transgenic (3  Tg-AD) mice was evaluated. A signiﬁcant reduction
in hippocampal/subicular APP/Ab in latrepirdine-treated mice was
& 2013 Macmillan Publishers Limited

shown; however, no change in the levels of full-length APP,
soluble Ab1–40 and Ab1–42, Ab oligomers, glial ﬁbrillary acidic
protein, beta-site APP cleaving enzyme 1 and hippocampal tau
levels was observed. Interestingly, the number of the hippocampal
APP/Ab plaques in latrepirdine-treated mice was higher compared
with control mice.20 It is possible that latrepirdine accelerates the
deposition of insoluble Ab into plaques without changing the
levels of soluble Ab species.53 Overall these ﬁndings provide
evidence for latrepirdine’s ability to modulate protein
aggregation. Although there is currently no evidence of
latrepirdine’s ability to signiﬁcantly alter amyloid structure,
recent studies have identiﬁed other metabolic functions that
may be responsible for its ability to modulate protein aggregation.
In a study by Steele et al.,72 latrepirdine treatment elevated levels
of Ab in the extracellular media in mouse N2a neuroblastoma cells
and in isolated synaptoneurosomes from AD transgenic mice
(TgCRND8). In addition, an acute dose of latrepirdine administered
intraperitoneally led to an increased Ab concentration in the
interstitial ﬂuid of AD transgenic mice. This study showed a
surprising association of acute latrepirdine dosing with elevated
levels of extracellular Ab. It is suggested that latrepirdine-induced
changes in neurotransmission, coupled with altered synaptic
activity may account for the rapid changes in extracellular Ab
levels. Recent reports have shown that synaptic activity can
dynamically alter interstitial ﬂuid Ab levels in vivo; however, the
speciﬁc mechanisms responsible for latrepirdine’s effects are
unclear.72–74 In addition to modulating APP/Ab metabolism,
recent reports have shown latrepirdine to enhance activity of
intracellular protein degradation pathways such as autophagy.
Latrepirdine modulates protein degradation pathways
The autophagy–lysosome system represents a main intracellular
degradation pathway for clearance of protein aggregates and
damaged organelles in eukaryotic cells.75 Modulating the cellular
degradation pathways to enhance clearance of protein aggregates
is gaining interest as a therapeutic strategy in several neurodegenerative disorders featuring abnormal protein accumulation.
In our recent report, a yeast model (Saccharomyces cerevisiae) was
used to investigate whether latrepirdine can modulate autophagy
and reduce levels of Ab42 aggregates. It was shown that
latrepirdine upregulated yeast autophagic markers including
vacuolar (lysosomal) activity and increased transport of Atg8
(autophagy-related protein 8) to the vacuole. Using an in vitro
GFP-tagged Ab yeast expression system, we showed that
latrepirdine signiﬁcantly reduced GFP-Ab42 in wild-type
compared with the autophagy-deﬁcient mutant (Atg8D). Further,
latrepirdine treatment attenuated Ab42-induced toxicity in wildtype cells but not in the Atg8D mutant. Taken together, these
ﬁndings provided evidence for a novel mechanism of action for
latrepirdine in reducing intracellular accumulation of Ab42 and
attenuation of Ab oligomer-induced toxicity via activation of
autophagy.51
Similar observations of latrepirdine-induced autophagy were
demonstrated in mammalian models.21,22 Treatment of cultured
mammalian cells with latrepirdine led to enhanced mammalian
target of rapamycin- and Atg5-dependent autophagy. Also,
latrepirdine treatment of TgCRND8 transgenic mice was associated with improved learning behaviour and with a reduction
in accumulation of Ab42 and a-synuclein. The induction of
autophagy was associated with decreased intracellular Ab
accumulation and a trend towards increased secreted Ab. These
changes are consistent with the previous report showing that
latrepirdine stimulates secretion of APP metabolites,72 suggesting
that latrepirdine may reduce intracellular APP/Ab accumulation
through stimulation of intracellular catabolic pathways.22
Latrepirdine was also shown to protect yeast against cytotoxicity
associated with a-synuclein expression, and this appeared to
Translational Psychiatry (2013), 1 – 9
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Table 2.

Mechanisms of action: latrepirdine

Cellular target/pathway

Drug activity

Ion channels and
receptor activity

Inhibits voltage-gated calcium channels
Interacts with L-type Ca2 þ channel, sodium channel, hERG potassium channel and transporter for
norepinephrine
Blocks histamine receptor (H1 and H2) activity
Inhibits NMDA receptors and potentiates activity of AMPA-receptors
Inhibits a-adrenergic receptors (a1A, a1B, a1D, and a2A), imidazoline I2 receptor and serotonin 5-HT2c,
5-HT5A, 5-HT6 receptors

Mitochondrial activity

Protein aggregation

Reference
5
17
6,7
37
17

Modulate the mitochondrial PTP and suppresses opening of PTP induced by neurotoxins
Attenuates Ca2 þ -induced mitochondrial swelling
Improves mitochondrial function on aspects such as mitochondrial membrane potential and ATP synthesis
Protects mitochondrial membrane integrity
Enhanced CGU in aged mice
Restore the toxic effects of Ab on mitochondrial morphology, respiratory chain complex and enlarged
mitochondrial mass

39

Reduces the number of TDP-43 aggregates in neuroblastoma cells
Reduces the number of amyloid deposits in the spinal cord of over expressing g-synuclein mice
Reduces accumulation of hippocampal/subicular APP/Ab and a-synuclein in mice
Elevates secretion of Ab in the extracellular media in neuronal cells and AD transgenic mice
Reduces GFP-Ab42 in wild-type compared with the autophagy-deficient mutant (Atg8D) in yeast model

74

68
18
19
70
69

14
20–22
76
55

Protein degradation
pathways

Upregulates autophagic markers in yeast model
Enhances mTOR- and Atg5-dependent autophagy cultured mammalian cells
Shows increased UPS activity in over expression g-synuclein mice model

55

Neuroprotective
functions

Inhibits MAO deaminating dopamine and serotonin, decrease dopamine metabolism and increase
noradrenaline level in the rat brain
Inhibits of both acetylcholine esterase and butyrylcholine esterase.
Restores TWAA performance in rats injected with AF64A
Prevents development of convulsions and death caused by NMDA induced toxicity in mice
Reduces amphetamine induced striatal dopamine depletion in mice and promote hippocampusdependent learning in both appetitive and inhibitory tasks in mice
Enhance memory and learning in a primate model
Increases hippocampal neurogenesis in the mouse model
Reduces the development of motor dysfunction in overexpressing synuclein mice model
Improves spatial memory function and behaviour in AD transgenic mice
Protects cultured cells against Ab toxicity

46

22
75

47
15
5
50
52
19
14
22
5,18,55

Abbreviations: Ab, b-amyloid; AD, Alzheimer’s disease; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; Atg5, autophagy-related protein 5; CGU,
cerebral glucose utilization; hERG, human ether-a-go-go-related gene; MAO, monoamine oxidase; mTOR, mammalian target of rapamycin; NMDA, N-methyl-Daspartate PTP, permeability transition pore; TDP-43, TAR DNA-binding protein 43; TWAA, two-way active avoidance; UPS, ubiquitin proteosome.

occur via induction of autophagy. Latrepirdine also stimulated
the degradation of a-synuclein in differentiated human neuroblastoma cells, and in mouse brain following chronic
administration, in parallel with elevation of the levels of markers
autophagic activity.21 In a more recent study, latrepirdine-treated
Thy1mgSN mice showed increased ubiquitin proteosome activity,
suggesting that it also stimulates other intracellular systems, in
addition to autophagy, that may contribute to the elimination of
pathological protein aggregates.71
SYNTHESIS AND ACTIVITY OF LATREPIRDINE-RELATED
COMPOUNDS
Latrepirdine is a small heterocyclic molecule with different
conformations and a relatively complicated pharmacology. As
described above latrepirdine can modulate receptor activity,
protect mitochondrial function, modulate intracellular catabolic
pathways and reduce amyloid aggregates and pathology in
cellular and neurodegenerative mice models (Table 2). A wide
range of cellular functions and broad concentration ranges
(0.1–100 mM) are required to achieve latrepirdine’s proposed biological activities. Some of these drug interactions have also been
suggested to be important for its cognitive-enhancing functions;
however, it has been difﬁcult to identify one particular pathway
Translational Psychiatry (2013), 1 – 9

as a target for latrepirdine in AD and other neurodegenerative
diseases.
Latrepirdine is known for its wide array of neuronal functions
and hence synthesis of structural analogues and assessment of
their effects on the therapeutic targets presents obvious value for
developing novel drugs for dementia treatment. In an attempt to
isolate potent histamine receptor antagonists, a recent study
tested synthesized latrepirdine analogues of 2,3,4,5-tetrahydro1H-pyrido[4,3-b]indoles 3 and 4 for their ability to interact with
histamine H1 receptors.76 The novel compounds demonstrated
much higher afﬁnity to all of the receptors studied as compared
with latrepirdine. Steric orientation of 5-styryl substitution was
shown to have an important role in the afﬁnity of the molecules to
5-HT6 and H1 receptors. The speciﬁcity proﬁles showed that
similar to latrepirdine, the new 2,3,4,5-tetrahydro-1H-pyrido
[4,3-b]indoles 3 and 4 display a broad spectra of potential
pharmacological activities including adrenergic, dopaminergic,
histaminergic, serotonergic as well as some ion channel targets.
Although promising, the biological activity of these novel
compounds will require further assessment and target validation
in cellular and animal models.
Latrepirdine contains a backbone structure of b-carboline
(9H-pyrido[3,4-b]indole), a bioactive class of compounds found
naturally in alkaloids produced in plants and known for their
& 2013 Macmillan Publishers Limited
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broad spectrum biological activity. The family of b-carboline
alkaloids, characterized by a core indole structure and a pyridine
ring affect multiple central nervous system targets. These include
the 5-hydroxytryptamine receptor subtypes 5-HT2 and 5-HT1A,77
the NMDA receptor,78 monoamine oxidase-A79 and dopaminergic
signaling pathways.80,81 In addition to these targets, the
b-carboline alkaloid, harmine, has recently been reported to be
a high-afﬁnity inhibitor of dual-speciﬁcity tyrosine phosphorylation-regulated kinase 1A activity, a member of the dualspeciﬁcity tyrosine phosphorylation-regulated kinase family that
has a signiﬁcant role in signaling pathways regulating cell
proliferation involved in brain development.82 A new class of
carboline compound that enhance hippocampal neurogenesis
and ameliorate cognitive decline were identiﬁed in an in vivo
screen in search of chemicals capable of enhancing neuron
formation in adult mice. In more recent studies, P7C3 has shown
the ability to reduce neurodegeneration in ALS and PD models.
P7C3 was shown to block MPTP-mediated cell death of
dopaminergic neurons in the substantia nigra of adult mice, a
model of PD55 and protect spinal cord motor neurons from cell
death in the G93A-SOD1 mutant mouse model of ALS.57 These
observations provide further evidence for the neuroprotective
functions of the carboline scaffold and raise the possibility that
latrepirdine and P7C3 compounds may operate via a common
mechanistic pathway.
CONCLUSION
To date, no preventive or disease-modifying drugs are available
for the treatment of neurodegenerative diseases including AD,
the leading cause of dementia. Studies have demonstrated
neuroprotective functions for latrepirdine and related class of
molecules including the b-carbolines and aminopropyl carbazoles.
However, the precise mechanism(s) underlying their cognitive beneﬁts in AD, HD and other neurodegenerative disease
models is unclear. Further investigation of the speciﬁc cellular
targets and biochemical pathways underlying their neuroprotective functions in disease models can provide the basis for
structure-based drug design. Such target-speciﬁc compounds
may offer promise for the future in the treatment of neurodegenerative diseases.
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